title: The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease.
abstract: Fabry disease (McKusick 301500) is an X-linked lysosomal storage disorder secondary to deficient alpha-galactosidase A activity which leads to the widespread accumulation of globotriaosylceramide (Gb(3)) and related glycosphingolipids, especially in vascular smooth-muscle and endothelial cells. We have recently shown that the myocardial perfusion reserve of Fabry patients is significantly decreased. Thus, in the present study we investigated, whether it can be improved with enzyme replacement therapy (ERT). Ten patients (7 male, 3 female; mean age 34, range 19-49 years) with confirmed Fabry disease were approved for this uncontrolled, open-label study. Myocardial perfusion was measured at rest and during dipyridamole-induced hyperaemia by positron emission tomography and radiowater. Myocardial perfusion reserve was calculated as the ratio between maximal and resting perfusion. Perfusion measurements were performed before and after 6 and 12 months of ERT by recombinant human alpha-galactosidase A (Fabrazyme, Genzyme). Plasma Gb(3) concentration decreased significantly and the patients reported that they felt better and suffered less pain after the ERT. However, neither resting or dipyridamole-stimulated myocardial perfusion nor myocardial perfusion reserve changed during the ERT. Pretreatment relative wall thickness correlated negatively with posttreatment changes in flow reserve (r = -0.76, p = 0.05) and positively with posttreatment changes in minimal coronary resistance (r = 0.80, p = 0.03). This study shows that 12 months of ERT does not improve myocardial perfusion reserve, although the plasma Gb(3) concentration decreases. However, individual variation in the response to therapy was large and the results suggest that the success of the therapy may depend on the degree of cardiac hypertrophy.
authors.affiliation: Turku PET Centre, University of Turku, PO Box 52, FIN-20521 Turku, Finland. riikka.kalliokoski@tyks.fi
authors.forename: R J
authors.initials: RJ
authors.lastname: Kalliokoski
authors.forename: I
authors.initials: I
authors.lastname: Kantola
authors.forename: K K
authors.initials: KK
authors.lastname: Kalliokoski
authors.forename: E
authors.initials: E
authors.lastname: Engblom
authors.forename: J
authors.initials: J
authors.lastname: Sundell
authors.forename: J C
authors.initials: JC
authors.lastname: Hannukainen
authors.forename: T
authors.initials: T
authors.lastname: Janatuinen
authors.forename: O T
authors.initials: OT
authors.lastname: Raitakari
authors.forename: J
authors.initials: J
authors.lastname: Knuuti
authors.forename: M
authors.initials: M
authors.lastname: Penttinen
authors.forename: J
authors.initials: J
authors.lastname: Viikari
authors.forename: P
authors.initials: P
authors.lastname: Nuutila
mesh_terms: D000328:Adult; D004452:Echocardiography; D000795:Fabry Disease / Q000188:drug therapy*; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D007527:Isoenzymes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010477:Perfusion; D049268:Positron-Emission Tomography; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors; D000519:alpha-Galactosidase / Q000627:therapeutic use*
chemical_list: D007527:Isoenzymes; D011994:Recombinant Proteins; D000519:alpha-Galactosidase; C459420:agalsidase beta